Skip to main content
The Globe and Mail
Support Quality Journalism.
The Globe and Mail
First Access to Latest
Investment News
Collection of curated
e-books and guides
Inform your decisions via
Globe Investor Tools
Just$1.99
per week
for first 24 weeks

Enjoy unlimited digital access
Cancel Anytime
Enjoy Unlimited Digital Access
Get full access to globeandmail.com
Just $1.99per week for the first 24weeks
Just $1.99per week for the first 24weeks
var select={root:".js-sub-pencil",control:".js-sub-pencil-control",open:"o-sub-pencil--open",closed:"o-sub-pencil--closed"},dom={},allowExpand=!0;function pencilInit(o){var e=arguments.length>1&&void 0!==arguments[1]&&arguments[1];select.root=o,dom.root=document.querySelector(select.root),dom.root&&(dom.control=document.querySelector(select.control),dom.control.addEventListener("click",onToggleClicked),setPanelState(e),window.addEventListener("scroll",onWindowScroll),dom.root.removeAttribute("hidden"))}function isPanelOpen(){return dom.root.classList.contains(select.open)}function setPanelState(o){dom.root.classList[o?"add":"remove"](select.open),dom.root.classList[o?"remove":"add"](select.closed),dom.control.setAttribute("aria-expanded",o)}function onToggleClicked(){var l=!isPanelOpen();setPanelState(l)}function onWindowScroll(){window.requestAnimationFrame(function() {var l=isPanelOpen(),n=0===(document.body.scrollTop||document.documentElement.scrollTop);n||l||!allowExpand?n&&l&&(allowExpand=!0,setPanelState(!1)):(allowExpand=!1,setPanelState(!0))});}pencilInit(".js-sub-pencil",!1); // via darwin-bg var slideIndex = 0; carousel(); function carousel() { var i; var x = document.getElementsByClassName("subs_valueprop"); for (i = 0; i < x.length; i++) { x[i].style.display = "none"; } slideIndex++; if (slideIndex> x.length) { slideIndex = 1; } x[slideIndex - 1].style.display = "block"; setTimeout(carousel, 2500); } //

Profound Medical Corp TSX: PRN-T

Today's Change
Volume
Real-Time Last Update TSX Last Sale

More stories below advertisement

Latest Press Releases

Profound Medical to Participate in June Investor Conferences
- GlobeNewswire - Tue May 25, 3:30PM CDT
GlobeNewswire - CMTX
Tue May 25, 3:30PM CDT
Profound Medical Corp. (TSX: PRN; NASDAQ: PROF) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, announced today that management will participate in two investor conferences in June.
Profound Medical Announces Voting Results from the 2021 Annual Meeting of Shareholders and Management Changes
- GlobeNewswire - Wed May 19, 7:08PM CDT
GlobeNewswire - CMTX
Wed May 19, 7:08PM CDT
Profound Medical Corp. (TSX: PRN; NASDAQ: PROF) ("Profound" or the "Company") is pleased to announce the voting results from its Annual Meeting of Shareholders that was held today (the "Meeting"). A total of 11,810,287 common shares, representing 58.044% of the common shares outstanding, were represented in person and by proxy at the Meeting.
Profound Medical Announces First Quarter 2021 Financial Results
- GlobeNewswire - Wed May 12, 3:13PM CDT
GlobeNewswire - CMTX
Wed May 12, 3:13PM CDT
Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today reported financial results for the first quarter ended March 31, 2021.
Profound Medical Corp. to Host Earnings Call
- ACCESSWIRE - Wed May 12, 1:30PM CDT
ACCESSWIRE - CMTX
Wed May 12, 1:30PM CDT
NEW YORK, NY / ACCESSWIRE / May 12, 2021 / Profound Medical Corp. (TSX:PRN) will be discussing their earnings results in their 2021 First Quarter Earnings call to be held on May 12, 2021 at 4:30 PM Eastern Time.
Profound Medical and Akumin Enter into U.S. Multi-Center Commercial Agreement for TULSA-PRO(R)
- GlobeNewswire - Thu May 6, 7:52AM CDT
GlobeNewswire - CMTX
Thu May 6, 7:52AM CDT
Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced the signing of a multi-site imaging center agreement for TULSA-PRO with Akumin Inc. (NASDAQ/TSX:AKU) ("Akumin"), a leading provider of freestanding, fixed-site outpatient diagnostic imaging services in the United States.
Akumin and Profound Medical Enter into U.S. Multi-Center Commercial Agreement for TULSA-PRO®
- CNW Group - Thu May 6, 6:00AM CDT
CNW Group - CMTX
Thu May 6, 6:00AM CDT
Akumin and Profound Medical Enter into U.S. Multi-Center Commercial Agreement for TULSA-PRO®
Profound Medical to Release First Quarter 2021 Financial Results on May 12 - Conference Call to Follow
- GlobeNewswire - Wed Apr 21, 3:30PM CDT
GlobeNewswire - CMTX
Wed Apr 21, 3:30PM CDT
Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, will announce its first quarter 2021 financial results after market close on Wednesday, May 12, 2021.
Profound Medical to Participate in the 2021 Bloom Burton & Co. Virtual Healthcare Investor Conference
- GlobeNewswire - Wed Apr 14, 3:30PM CDT
GlobeNewswire - CMTX
Wed Apr 14, 3:30PM CDT
Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, announced today that management will present an update on the Company's business at the 2021 Bloom Burton & Co. Virtual Healthcare Investor Conference on Wednesday, April 21, 2021 at 1:30 p.m. ET.
Profound Medical Announces the Appointment of Cynthia Lavoie to its Board of Directors
- GlobeNewswire - Wed Mar 3, 6:00AM CST
GlobeNewswire - CMTX
Wed Mar 3, 6:00AM CST
Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) ("Profound"), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, announced today the appointment of Cynthia Lavoie Ph.D., MBA, to its Board of Directors.
Profound Medical Announces Fourth Quarter and Full Year 2020 Financial Results
- GlobeNewswire - Tue Mar 2, 3:02PM CST
GlobeNewswire - CMTX
Tue Mar 2, 3:02PM CST
Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today reported financial results for the fourth quarter and full year ended December 31, 2020.

More stories below advertisement

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2021.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies